Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 influence on pneumococcal and influenza vaccine responses in older adults
NL-OMON49987Withdrawn
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Oct 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of 23-valent pneumococcal polysaccharide vaccine and influenza vaccine in pneumococcal disease and influenza (2 cohorts), sponsored by National Institute for Public Health and the Environment. Planned start Oct 2020; status: withdrawn.
02
Drugs
23-valent pneumococcal polysaccharide vaccineinfluenza vaccine
03
Conditions
pneumococcal diseaseinfluenza
Beyond the preview
Go deeper on NL-OMON49987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49987.